Acquired Autoimmune Hemolytic Anemia Market Forecast 2026–2030 Highlighting Expansion Across Industries
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Acquired Autoimmune Hemolytic Anemia Market In 2026 And 2030?
The market size for acquired autoimmune hemolytic anemia has experienced substantial expansion in recent years. This market is projected to grow from $2.14 billion in 2025 to $2.29 billion in 2026, showing a compound annual growth rate (CAGR) of 7.1%. The historical increase can be ascribed to improved autoimmune disease diagnosis, reliance on corticosteroid treatment, specialization in hospital hematology, an increase in malignancy-linked anemia cases, and the availability of diagnostic tests.
The market size for acquired autoimmune hemolytic anemia is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $3.01 billion, demonstrating a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period can be attributed to factors such as increased rare disease awareness, the adoption of biologic therapies, the integration of advanced diagnostics, funding for hematology research, and the development of personalized treatment protocols. Key trends expected over the forecast horizon encompass a greater utilization of targeted immunosuppressive treatments, the growing acceptance of rituximab-based therapies, an expansion in hospital-centric hematology care, the widespread adoption of enhanced diagnostic testing, and the broadening of rare disease treatment programs.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp
Which Strong Drivers Are Impacting The Acquired Autoimmune Hemolytic Anemia Market Growth?
The rising occurrence of autoimmune conditions is anticipated to fuel the expansion of the acquired autoimmune hemolytic anemia market in the future. Autoimmune disorders occur when the immune system mistakenly targets the body’s own healthy cells and tissues, perceiving them as dangerous foreign invaders. The escalating prevalence of these disorders is primarily linked to an increase in environmental triggers and lifestyle shifts that can impair immune system regulation. This growing prevalence of autoimmune disorders contributes to a higher incidence of acquired autoimmune hemolytic anemia, as individuals with autoimmune conditions are more likely to develop secondary AIHA due to immune system dysregulation. For instance, in 2023, the Gastro-Intestinal Epidemiology Consortium (CanGIEC), a Canada-based national network of researchers and clinicians, estimated the prevalence of inflammatory bowel disease at 825 cases per 100,000 people. This prevalence is forecasted to rise by 2.44% annually, reaching 1,075 cases per 100,000 people by 2035. Therefore, the increasing prevalence of autoimmune disorders will stimulate the growth of the acquired autoimmune hemolytic anemia market.
Which Segment Categories Are Included In The Acquired Autoimmune Hemolytic Anemia Market Segment Analysis?
The acquired autoimmune hemolytic anemia market covered in this report is segmented –
1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Specialty Clinics, Research Institutions
Subsegments:
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing
Which Trends Are Contributing To Changes In The Acquired Autoimmune Hemolytic Anemia Market?
Leading companies within the acquired autoimmune hemolytic anemia market are prioritizing progress in targeted therapeutic approaches, such as neonatal Fc receptor (FcRn) blockers. This focus aims to enhance the effectiveness of treatments, improve outcomes for both mothers and fetuses, and offer more potent interventions for high-risk pregnancies complicated by severe hemolytic disease. An FcRn blocker operates as a therapeutic antibody designed to obstruct the neonatal Fc receptor, which plays a role in the recycling of immunoglobulin G (IgG) antibodies within the body. This action consequently lowers the levels of pathogenic antibodies responsible for destroying red blood cells and causing hemolytic issues in both maternal and fetal populations. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical and healthcare company, was granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for its drug nipocalimab. This designation was for treating individuals at significant risk for severe hemolytic disease of the fetus and newborn (HDFN). Nipocalimab functions by precisely inhibiting the neonatal Fc receptor (FcRn), thereby decreasing maternal IgG antibody concentrations that cross the placenta and target fetal red blood cells. This mechanism helps in preventing severe hemolytic disease, reducing the necessity for intrauterine transfusions, and improving results for pregnancies at risk. Specifically, nipocalimab acts on FcRn-mediated IgG recycling without impacting other immune functions.
Who Are The Active Companies Shaping The Acquired Autoimmune Hemolytic Anemia Market?
Major companies operating in the acquired autoimmune hemolytic anemia market are F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Novartis AG, Incyte Corporation, BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Johnson & Johnson, Merck KGaA, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, CSL Behring, Grifols S.A.
Get The Full Acquired Autoimmune Hemolytic Anemia Market Report:
Where Is The Acquired Autoimmune Hemolytic Anemia Market Primarily Concentrated By Region?
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Acquired Autoimmune Hemolytic Anemia Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Acquired Autoimmune Hemolytic Anemia Market 2026, By The Business Research Company
Autoimmune Disease Diagnosis Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report
Autoimmune Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Anemia And Other Blood Disorder Drugs Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
